Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Version: 8 May 2018
Length: 2 pages
Data source: Published sources
Share a link:
https://casecent.re/p/153400
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
In February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm's position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene's key drug, Revlimid. In response, Celgene's share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial investment.
Industry:
Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Version: 8 May 2018
Length: 17 pages
Data source: Published sources
About
Abstract
In February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm's position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene's key drug, Revlimid. In response, Celgene's share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial investment.
Settings
Industry:
Related
Subject category:
Finance, Accounting and Control
Published by:
Harvard Business Publishing
Version: 8 May 2018
Length: 17 pages
Data source: Published sources